APMD.US Apnimed, Inc. Common Stock

Healthcare Biotechnology USA Stocks
16.92 USD
Close of Nov 14, 2026
13.88 35.29
Market cap
USD 704M
P/E
2.3x
P/B
4.40x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is APMD.US undervalued?

Graham number
Price16.92
Graham value24.99
Discount32.3%

APMD.US trades 32.3% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Apnimed, Inc. Common Stock fundamental analysis

No fundamental analysis for Apnimed, Inc. Common Stock yet.

Apnimed, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Apnimed, Inc. Common Stock

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Full company profile